World Class Scientific Advisors and Management Join Sagene Pharmaceuticals

Oldsmar, FL, November 16, 2010 – Sagene Pharmaceuticals, Inc., a biopharmaceutical company focused on developing combinations of FDA-approved drugs to treat diseases associated with aging, today announced the addition of Albert J. Azzaro, Ph.D. and David V. Sheehan, M.D., M.B.A. to its leadership team and the establishment of a 7 person Scientific Advisory Board.

Sagene was formed in 2010 to commercialize patented vascular disease discoveries initiated by founder Dr. Tom Thomas in 2001. Sagene has data showing that selective MAO-B inhibitors, specifically selegiline (l-deprenyl), can reduce side effects and/ or enhance efficacy in combination with current treatments for erectile dysfunction (ED), pulmonary arterial hypertension (PAH), pain/inflammation and cardiovascular diseases by targeting multiple disease pathways not addressed by currently approved drugs. “We are excited to bring Dr. Azzaro and Dr. Sheehan and world-class scientific advisors to Sagene,” said Dr. Thomas, MD, PhD, Founder and CEO of Sagene. “Each has significant drug development experience with selegiline and are leaders in his or her field, and will provide invaluable expertise and guidance as Sagene develops its clinical program.” Sagene expects to hold a pre-IND meeting next year for its first drug combination, a patented combination with multiple actions targeting both CNS and end-organ tissue to improve the treatment of erectile dysfunction.

Dr. Azzaro joins Sagene as Acting Vice President of Research and Development and will lead clinical development efforts. He is a neuropharmacologist with more than 35 years of research experience in basic neuropharmacology, clinical pharmacology, pharmacokinetics, and drug development in neurological and psychiatric disorders. Dr. Azzaro served as Director of Scientific Operations at the Covance CNS Center (Covance, Inc.) and as Chief Scientific Officer with Somerset Pharmaceuticals, Inc. (acquired by Mylan Inc.) where he played a major role in the development, NDA preparation, and the 2006 FDA approval of the selegiline patch (EMSAM®) for the treatment of Major Depressive Disorder (MDD).

“I have been working with selegiline for thirty years, from the laboratory bench to clinical development and FDA approval” said Dr Azzaro. “Selegiline has many pharmacological actions in addition to its well know effect on brain dopamine neurotransmission. Some of these actions may prove useful in the treatment of

medical conditions other than Parkinson's disease and MDD. We have assembled a team of drug development experts who have worked with me in the past and are very familiar with the clinical pharmacology of selegiline and the drug development process. Our initial efforts will be to exploit our findings with selegiline on nitric oxide production and to test its effects as adjunctive treatment with phospodiesterase-5 (PDE-5) inhibitors, like sildenafil, in erectile dysfunction (ED). The urology literature tells us that many patients with ED may find a dual action product beneficial to their condition."

Dr. Sheehan joins Sagene as Vice President of Clinical Affairs. He is a clinical psychiatrist and expert in CNS clinical trial design. He has acted as a clinical affairs advisor for numerous large pharma and biotech companies and government organizations. Dr. Sheehan is a Distinguished University Health Professor Emeritus and former Professor of Psychiatry, Director Psychiatric Research at the University of South Florida and former Assistant Professor of Psychiatry at Harvard Medical School.

Sagene's new scientific advisors include several experts in drug development and the FDA regulatory process, including four experts, who along with Dr. Azzaro, directed the selegiline patch development program and FDA approval at Somerset Pharmaceuticals:

Lawrence Blob, M.D. is former Medical Director at Somerset Pharmaceuticals where he was a member of the development team for the selegiline NDA approval in MDD. Dr Blob is an expert on the design and clinical execution of dietary tyramine challenge studies that are often the subject of safety of selective MAO inhibitor drugs. Dr. Blob is a former emergency medicine physician.

Culley C. Carson III, M.D. is the Chief of Urology at UNC Chapel Hill and former Professor of Urology at Duke University. Dr Carson is a urology expert specializing in sexual dysfunction, urologic surgery, and prostate diseases and has participated in several pivotal ED clinical trials.

Robert Fielding, M.S. has over 25 years experience in pharma and biotech clinical research. He is a former Principal Scientist at NeXstar Pharmaceuticals and Pharmacologist at Nexagen and Somatogen.

Thomas Hochadel, Pharm.D has over 16 years experience in the planning and execution of clinical trials. Dr. Hochadel is the former Director of Clinical Research at Somerset Pharmaceuticals where he lead 2 IND's and more than 30 Phase I clinical studies for selegiline.

Sally Look, Ph.D. has over 20 years experience in CMC regulatory work for FDA submissions. Dr. Look is a former Review Chemist at FDA CDER and consultant to the Somerset Pharmaceuticals selegiline program.

Frances Mielach, Ph.D. has over 25 years experience in pharmaceutical regulations and FDA submission requirements. Dr. Mielach is a former VP, Regulatory and Scientific Affairs at Myriad Pharmaceuticals and Former Supervisor and Reviewer at FDA CDER. Dr Mielach consulted to the Somerset Pharmaceuticals selegiline development program and assisted in the NDA preparation for the selegiline patch (EMSAM®) for the treatment of Major Depressive Disorder (MDD).

George Nadackal, MS, Ph.D. has 20 years of leadership experience in drug discovery and development at West Coast Pharmaceutical companies. Dr. Nadackal is experienced in regulatory submissions and licensing processes and has authored preclinical and clinical sections of several IND's.

About Sagene Pharmaceuticals, Inc.
Sagene Pharmaceuticals is a biopharmaceutical company developing novel applications for combinations of FDA-approved drugs to treat diseases associated with aging. Sagene has shown that selective MAO-B inhibitors, specifically selegiline (l-deprenyl), can reduce side effects and enhance efficacy in combination with current treatments for erectile dysfunction (ED), pulmonary arterial hypertension (PAH), pain/inflammation and cardiovascular diseases by targeting multiple disease pathways not typically addressed by currently approved drugs. These novel actions of selegiline have been patented by Sagene. The combination approach for treating diseases with FDA-approved drugs to improve their therapeutic effect, reduces development risk, time and costs by utilizing the 505(b)(2) NDA approval process. Sagene has assembled a team of experts experienced in drug development, clinical trials and regulatory affairs. Sagene has conducted preclinical studies showing proof of concept and the benefits of selegiline in laboratory animals and human platelets. The company is headquartered in Oldsmar, FL.

For more information about Sagene Pharmaceuticals, please visit the Company's website at www.sagenepharma.com.

For Further Information Contact:

Prem Thomas
CFO and Cofounder
Sagene Pharmaceuticals
+1 919 452 7317
prem@sagenepharma.com